安慰剂对照试验的伦理辩护

伦理学研究 ›› 2013 (2): 124-127.

安慰剂对照试验的伦理辩护

王晓敏, 田勇泉

收稿日期:2012-10-09 出版日期:2013-03-10 发布日期:2022-01-05
作者简介:王晓敏,中南大学公共管理学院生命伦理学博士生,主要研究方向为生命伦理学。田勇泉,中南大学湘雅医学院教授,博士生导师,主要从事耳鼻喉科和生命伦理学研究。
基金资助:
国家社科基金重大项目“现代医疗技术中的生命伦理及其法律问题研究”(项目编号:11&ZD177);湖南省博士生科研创新项目“随机临床试验的伦理问题研究”(项目编号:CX2010B097)。

Received:2012-10-09 Online:2013-03-10 Published:2022-01-05

摘要/Abstract

摘要： 在临床试验中,当存在有效治疗方法时,采用安慰剂对照试验是否合乎道德,是近年来生命伦理学争论的焦点之一。本文认为,安慰剂对照试验的反对者低估了临床研究方法学和伦理学的复杂性,忽视了安慰剂对照试验的适用范围。方法学或科学上的必要性是安慰剂对照试验道德合理性的首要条件。安慰剂对照试验如果符合合理的风险/收益评估比以及“合理可得”或“可持续”标准,在缺乏检测敏感性的研究领域,在研究伦理审查委员会的监督下进行,是可以得到伦理辩护的。

中图分类号:

B82-057

王晓敏, 田勇泉. 安慰剂对照试验的伦理辩护[J]. 伦理学研究, 2013(2): 124-127.

参考文献

[1] 田少雷,邵庆翔.药物临床试验与GCP实用指南[M].北京: 北京大学医学出版社, 2010, (1).
[2] The World Medical Association. World Medical Association Declaration of Helsinki [EB/OL] .http://www.wma.net/e/policy/b3.htm.
[3] Benjamin Freedman, Charles Weijer, Kathleen CranleyGlass. Placebo orthodoxy in clinical research I: Empirical and methodological myths. The Journal of Law, Medicine & Ethics, 1996; 24:243-251.
[4] Ezekiel J. Emanuel, Franklin G. Miller. The Ethics of Placebo-controlled Trials - A Middle Ground, The New England Journal of Medicine, vol. 345, No.22 ,September 20, 2001.
[5] Lorraine G. Allan, Shepard Siegel. A Signal Detection Theory Analysis of the Placebo Effect.Evaluation& the Health Professions, vol. 25, no. 4, December 2002: 410-420.
[6] Mark J Bolland, P Alan Barber, Robert N Doughty, et al. Vascular events in healthy older women receiving calcium supplementation: Randomized controlled trial. British Medical Journal, January 2008; 336: 262.
[7] Jeremy Howick. Questioning the Methodologic Superiority of ‘Placebo’ over ‘Active’ Controlled Trials.TheAmerican Journal of Bioethics 2009.vol. 9(9): 34-48.
[8] Robert Temple, Susan S. Ellenberg. Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments, Part 1: Ethical and Scientific Issues. Annals of Internal Medicine, 2000; 133: 455-463.
[9] 周宏灏,袁洪.药物临床试验 [M],北京:人民卫生出版社,2011, (3).
[10] Henry Knowles Beecher. Ethics and clinical research.New England Journal of Medicine 1966; 274: 1354-1360.
[11] Brian Vastag. Helsinki Discord? A Controversial Declaration.JAMA, 2000;284(23):2983-2985.
[12] US Food and Drug Administration. Guidance for industry: E 10 choice of control group and related issues in clinical trials. May 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073139.pdf. Accessed September 5, 2012.
[13] Robert J. Levine. Placebo controls in clinical trials of new therapies for conditions for which there are known effective treatments. In Guess HA, Kleinman A, Kusek JW and Engel, LW (editors) The Science of the Placebo: Toward an Interdisciplinary Research Agenda, BMJ Books, London, 2002.
[14] Food and Drug Administration. Guidance for industry: botanical drug products.2004;9-10. http://www.fda.gov/cder/guidance/index.htm
[15] Rebecca Kukla. Resituating the Principle of Equipoise: Justice and Access to Care in Non-Ideal Conditions. Kennedy Institute of Ethics Journal, vol 17, no 3, September 2007:171-202.